Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | EDNRA | P25101 | 2/20 | 0.37 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6305877 | 0.70 | MAPT (0.46) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL3135177 | 0.69 | CYP1A2 (0.58) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL70993 | 0.68 | LMNA (0.54) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL29370508 | 0.68 | LMNA (0.54) | MAPTLMNATP53MAPK1CYP1A2 | |
| Benzene SCHEMBL27791155 | 0.68 | LMNA (0.54) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL25171318 | 0.68 | LMNA (0.54) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL1389126 | 0.67 | FGFR1 (0.42) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL4937596 | 0.66 | TP53 (0.59) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL29642916 | 0.66 | TP53 (0.59) | MAPTLMNATP53MAPK1CYP1A2 | |
| SCHEMBL25028023 | 0.66 | LMNA (0.54) | MAPTLMNATP53MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1784186-A4 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007117289-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| EP-1784186-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | Inotek Pharmaceuticals Corporation (US) | 2007-05-16 | — | — | EP | disclosed |
| US-7217709-B2 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1603567-A4 | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORP (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006009718-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | INOTEK PHARMACEUTICAL, CORP. (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1603567-A2 | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE THEREOF | Inotek Pharmaceuticals Corporation (US) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005009398-A2 | TETRACYCLIC BENZAMIDE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20040229895-A1 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | PDE3A, PDE3B, PDE5A | MAPT 1261/4885LMNA 1627/4885TP53 4837/4885 |
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | TBC1D5, TBC1D15, BAD | MAPT 3621/4885LMNA 1926/4885TP53 886/4885 |
| US-20040229895-A1 | Tetracyclic benzamide derivatives and methods of use thereof | TBC1D5, TBC1D15, BAD | MAPT 3621/4885LMNA 1926/4885TP53 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.